Dr. Klein Receives American Headache Society Distinguished Service Award
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Dr. Cook gives an overview of symptoms and treatment of Parkinson Disease.
While we might not have clear progress, we do have an advance.